Colitis Ulcerative

Top drugs studied for this disease

EMA approval · 2026-08-26
EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG
Regulatory authorization for Skyrizi (risankizumab) by AbbVie Deutschland GmbH & Co. KG across multiple inflammatory diseases.
EMA withdrawal · 2026-07-28
EMA Withdrawn: Inflectra (infliximab) — Pfizer Europe MA EEIG
The EMA has withdrawn Inflectra (infliximab) from the market.
EMA withdrawal · 2020-03-25
EMA Withdrawn: Kromeya (adalimumab) — Fresenius Kabi Deutschland GmbH
EMA has withdrawn Kromeya (adalimumab) from Fresenius Kabi Deutschland GmbH, effective 2019, affecting multiple inflammatory diseases.